Federally-Listed PSOs

Below is a list of PSOs that are currently listed by AHRQ. A health care provider can only obtain the confidentiality and privilege protections of the Patient Safety Act by working with a Federally-listed PSO.

Use the categories on the left to filter the list of PSOs or search a PSO name.

Note: AHRQ updates the PSO information contained within the directories weekly, as needed; changes are made when there are newly listed PSOs and/or when existing information requires revision. Changes that would otherwise be effective on a weekend day or holiday will be effective on the next business day. Information contained in the directories is based on attestations that the PSOs provide. To update PSO contact information, please use the Change of Listing Information form; to update profile information, please go to the PSO PPC Web site.

There are 83 total PSOs listed by AHRQ.

HCA Patient Safety Organization, LLC - P0157
Component of Parent Org(s):
  • HCA Holdings, Inc. (direct parent: EP Holdco, LLC)
Effective Date and Time of Initial Listing: April 9, 2014 12:01 AM ET
Street Address: One Park Plaza, Nashville, Tennessee 37203
PSO Phone Number: (615) 344-2293
Point of Contact: Sharon Weidner Hickman
Point of Contact Phone: 615-344-1254
Point of Contact Email: Sharon.Hickman@hcahealthcare.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 04/09/2018 through 04/08/2020
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
Surgical Outcomes & Quality Improvement Center (SOQIC) - P0152
Component of Parent Org(s):
  • Northwestern University - Feinberg School of Medicine
Effective Date and Time of Initial Listing: January 15, 2014 12:01 AM ET
Street Address: 633 N. St. Clair Street, 20th floor, Chicago, Illinois 60611
PSO Phone Number: (312) 503-3762
Point of Contact: Remi Love MPPA
Point of Contact Phone: (312) 503-3947
Point of Contact Email: remi-love@northwestern.edu (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 01/15/2018 through 01/14/2020
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No